Golden State Equity Partners’s LeMaitre Vascular LMAT Stock Holding History

Golden State Equity Partners’s Portfolio LMAT Stock Details LMAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20	Closed	-$2.18K	–	1129
2026 Q1	$2.18K	Buy	+20	New	+$1.91K	﹤0.01%	1659

Other funds holding LMAT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Golden State Equity Partners's LMAT Position: Q2 2026 in Review

Golden State Equity Partners sold out of LeMaitre Vascular (LMAT) in Q2 2026, closing a stake of 20 shares — an estimated $2.18K sold.

Golden State Equity Partners first reported a position in LMAT in Q1 2026 and held it in 1 quarter. The position peaked at $2.18K in Q1 2026. 326 funds tracked by Wall St. Rank hold LMAT as of Q2 2026.

Golden State Equity Partners reported no remaining LeMaitre Vascular position as of Q2 2026 after selling out during the quarter.
Golden State Equity Partners sold 20 LeMaitre Vascular shares in Q2 2026, an estimated $2.18K.
Golden State Equity Partners first reported a position in LeMaitre Vascular in Q1 2026 and held it in 1 quarter.
Golden State Equity Partners's LeMaitre Vascular position peaked at $2.18K in Q1 2026.
326 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.